Isomorphic Labs, a London startup founded as a Google DeepMind spinout and led by Sir Demis Hassabis, announced a $5 billion Series C round led by Greenoaks and Sequoia Capital, with participation from Alphabet, Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund, pharmaphorum reported. The round brings total funding since the company was founded in 2021 to more than $7.7 billion and an estimated $50 billion paper value. Alphabet described its backing as a "continued significant investment," Isomorphic said Tuesday, The financing comes after a $2.1 billion Series B announced in May, according to BioPharma Dive.
Isomorphic has not yet moved any drug candidates into clinical trials. It has signed research partnerships with Johnson & Johnson, Novartis and Eli Lilly. Isomorphic said the funding will go toward improving its foundational simulation models, advancing its internal and partnered drug pipeline, and establishing a worldwide AI-driven bioengineering infrastructure.
The company's platform centers on IsoDDE, a drug design engine composed of foundational simulation AI models that forecast 3D protein structures and how they interact with drug candidates, estimate binding affinities, and identify new binding pockets. Isomorphic said the platform is generating positive preclinical results in oncology and immunology for internal programs and partners, "setting the stage for clinical entry". Hassabis said in a statement: "Our drug design engine is generating molecules with unprecedented precision and speed".
BioPharma Dive data shows the Series C is the largest financing it has tracked since 2022, and Isomorphic's two multibillion-dollar rounds are the biggest venture infusions this year among the 26 biotech firms the publication follows. Yahoo Finance reported Tuesday that the round comes as technology stocks sell off, but investors in Isomorphic appear unfazed. Bristol Myers Squibb, Merck & Co., Eli Lilly, and Novo Nordisk are among the large drugmakers that have announced substantial AI investments or partnerships this year, but no medicine designed by AI has been approved, and experts say the technology is unlikely to be a quick fix.
Sources: pharmaphorum, Yahoo! Finance, BioPharma Dive
To report an error in this article, write to corrections@venturistnews.com. Corrections log.
Elliot Marsh covers startups, IPO filings and the money behind them for Venturist. Elliot writes from SEC filings, company announcements and published reporting.
